Over the past decade, China’s biopharma innovation has undergone a deep and systemic “efficiency revolution,” centered on a reshaping of system capabilities defined by scale, speed, and cost. As regulatory rules have progressively aligned with international standards, and as capital, talent, and the academia-industry ecosystem have rapidly coalesced, China has moved from being a follower on the margins of the global innovation system into an increasingly influential innovation hub. This accumulation of capabilities has elevated China into the forefront of global biopharma innovation.
Looking to the next decade, China’s biopharma innovation stands at a new inflection point. The key question is whether efficiency gains can be translated into globally recognized innovation value—with the accompanying price tag. Moving from efficiency advantage to value leadership means shifting from an innovation model defined by efficiency to one defined by quality, originality, system maturity, and long-term sustainability. This transition will materially reshape China’s role in the global innovation system and redefine its trajectory over the next decade.
In this report, we first examine China’s new global stance in biopharma innovation and the evolving innovation paradigm that will define the years ahead. We then turn to the resilience of China’s innovation ecosystem, unpacking the key enablers that support its continued evolution, especially the ecosystem’s capacity for self-reinforcement and resilience, and how these will shape the boundaries and upper limits of innovation in the next decade.